Cargando…

Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice

OBJECTIVE: To assess the real-world comparative effectiveness of switching from natalizumab (NTZ) to a moderate-efficacy (Mod) disease-modifying therapy (DMT) vs high-efficacy therapy (HET) in patients with multiple sclerosis (MS). METHODS: Patients discontinuing NTZ at two MS centers (n = 556) who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hersh, Carrie M., Harris, Haleigh, Conway, Devon, Hua, Le H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837445/ https://www.ncbi.nlm.nih.gov/pubmed/33510948 http://dx.doi.org/10.1212/CPJ.0000000000000809

Ejemplares similares

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population
por: Conway, Devon S, et al.
Publicado: (2020)

Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
por: Hersh, Carrie M, et al.
Publicado: (2020)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

DMT alters cortical travelling waves
por: Alamia, Andrea, et al.
Publicado: (2020)

DMT Models the Near-Death Experience
por: Timmermann, Christopher, et al.
Publicado: (2018)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
por: Barker, Steven A.
Publicado: (2022)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

Correction: DMT alters cortical travelling waves
por: Alamia, Andrea, et al.
Publicado: (2020)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Neural correlates of the DMT experience assessed with multivariate EEG
por: Timmermann, Christopher, et al.
Publicado: (2019)

Regulation of DMT1 on autophagy and apoptosis in osteoblast
por: Liu, Fei, et al.
Publicado: (2017)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience
por: Lawrence, David Wyndham, et al.
Publicado: (2022)

Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
por: Havla, Joachim, et al.
Publicado: (2013)

Human brain effects of DMT assessed via EEG-fMRI
por: Timmermann, Christopher, et al.
Publicado: (2023)

Neural network models for DMT-induced visual hallucinations
por: Schartner, Michael M, et al.
Publicado: (2020)

CPT—DMT Correlations on Regional Soils from Croatia
por: Grabar, Kristijan, et al.
Publicado: (2022)

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
por: Chang, Ih, et al.
Publicado: (2020)

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis
por: O'Leary, Shirley, et al.
Publicado: (2023)

Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use
por: Sherwood, Alexander M., et al.
Publicado: (2020)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Regulation of DMT1 on Bone Microstructure in Type 2 Diabetes
por: Zhang, Wei-Lin, et al.
Publicado: (2015)

Stability Evaluation of DMT and Harmala Alkaloids in Ayahuasca Tea Samples
por: de Oliveira Silveira, Gabriela, et al.
Publicado: (2020)

A narrative synthesis of research with 5-MeO-DMT
por: Ermakova, Anna O, et al.
Publicado: (2021)

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
por: Longinetti, Elisa, et al.
Publicado: (2022)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
por: Wang, Li, et al.
Publicado: (2018)

Interferon-beta-1a/natalizumab: Lack of efficacy: case report
Publicado: (2021)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_d7mgrpfcg28timhgstpu2nshga